Prognosis of seronegative patients in a large prospective cohort of patients with early inflammatory arthritis

Journal of Rheumatology

Volumn 41, Issue 12, 2014, Pages 2361-2369

  Barra, Lillian ^a   Pope, Janet E ^a   Orav, John E ^b   Boire, Gilles ^c   Haraoui, Boulos ^d   Hitchon, Carol ^e   Keystone, Edward C ^f   Thorne, J Carter ^e   Tin, Diane ^e   Bykerk, Vivian P ^g,h  

^a UNIVERSITY OF WESTERN ONTARIO   (Canada)

^b HARVARD UNIVERSITY   (United States)

^c UNIVERSITÉ DE SHERBROOKE   (Canada)

^d UNIVERSITÉ DE MONTRÉAL   (Canada)

^e UNIVERSITY OF MANITOBA   (Canada)

^f SOUTHLAKE REGIONAL HEALTH CENTRE   (Canada)

^g UNIVERSITY OF TORONTO   (Canada)

^h Department of Obstetrics Gynecology   (United States)

Author keywords

Anticitrullinated protein antibodies; Prognosis; Rheumatoid arthritis; Rheumatoid factor

Indexed keywords

CYCLIC CITRULLINATED PEPTIDE ANTIBODY; RHEUMATOID FACTOR; ANTIIDIOTYPIC ANTIBODY; BIOLOGICAL MARKER; CYCLIC CITRULLINATED PEPTIDE; CYCLOPEPTIDE;

ADULT; ARTICLE; COHORT ANALYSIS; CONTROLLED STUDY; DAS28; DISEASE ACTIVITY; DISEASE ASSOCIATION; DISEASE DURATION; DISEASE SEVERITY; FEMALE; FOLLOW UP; HUMAN; JOINT SWELLING; MAJOR CLINICAL STUDY; MALE; PROGNOSIS; PROSPECTIVE STUDY; REMISSION; RHEUMATOID ARTHRITIS; AGE; AGED; ARTHRITIS, RHEUMATOID; BLOOD; COMPARATIVE STUDY; IMMUNOLOGY; MIDDLE AGED; ONSET AGE; SEVERITY OF ILLNESS INDEX; SEX DIFFERENCE;

ADULT; AGE FACTORS; AGE OF ONSET; AGED; ANTIBODIES, ANTI-IDIOTYPIC; ARTHRITIS, RHEUMATOID; BIOLOGICAL MARKERS; COHORT STUDIES; FEMALE; HUMANS; MALE; MIDDLE AGED; PEPTIDES, CYCLIC; PROGNOSIS; PROSPECTIVE STUDIES; RHEUMATOID FACTOR; SEVERITY OF ILLNESS INDEX; SEX FACTORS;

EID: 84915818842     PISSN: 0315162X     EISSN: 14992752     Source Type: Journal    
DOI: 10.3899/jrheum.140082     Document Type: Article

References (31)

1. Nielen MM, van Schaardenburg D, Reesink HW, van de Stadt RJ, van der Horst-Bruinsma IE, de Koning MH, et al. Specific autoantibodies precede the symptoms of rheumatoid arthritis: a study of serial measurements in blood donors. Arthritis Rheum 2004;50:380-6.
2. Whiting PF, Smidt N, Sterne JA, Harbord R, Burton A, Burke M, et al. Systematic review: accuracy of anti-citrullinated peptide antibodies for diagnosing rheumatoid arthritis. Ann Intern Med 2010;152:456-64.
3. Barra L, Pope J, Bessette L, Haraoui B, Bykerk V. Lack of seroconversion of rheumatoid factor and anti-cyclic citrullinated peptide in patients with early inflammatory arthritis: a systematic literature review. Rheumatology 2011;50:311-6.
4. Barra L, Bykerk V, Pope JE, Haraoui BP, Hitchon CA, Thorne JC, et al. Anticitrullinated protein antibodies and rheumatoid factor fluctuate in early inflammatory arthritis and do not predict clinical outcomes. J Rheumatol 2013;40:1259-67.
5. Guzian MC, Carrier N, Cossette P, de Brum-Fernandes AJ, Liang P, Menard HA, et al. Outcomes in recent-onset inflammatory polyarthritis differ according to initial titers, persistence over time, and specificity of the autoantibodies. Arthritis Care Res 2010;62:1624-32.
6. Mjaavatten MD, van der Heijde DM, Uhlig T, Haugen AJ, Nygaard H, Bjorneboe O, et al. Should anti-citrullinated protein antibody and rheumatoid factor status be reassessed during the first year of followup in recent-onset arthritis? A longitudinal study. J Rheumatol 2011;38:2336-41.
7. Willemze A, Bohringer S, Knevel R, Levarht EW, Stoeken-Rijsbergen G, Houwing-Duistermaat JJ, et al. The ACPA recognition profile and subgrouping of ACPA-positive RA patients. Ann Rheum Dis 2012;71:268-74.
8. Frisell T, Holmqvist M, Kallberg H, Klareskog L, Alfredsson L, Askling J. Familial risks and heritability of rheumatoid arthritis: role of rheumatoid factor/anti-citrullinated protein antibody status, number and type of affected relatives, sex, and age. Arthritis Rheum 2013;65:2773-82.
9. Huizinga TW, Amos CI, van der Helm-van Mil AH, Chen W, van Gaalen FA, Jawaheer D, et al. Refining the complex rheumatoid arthritis phenotype based on specificity of the HLA-DRB1 shared epitope for antibodies to citrullinated proteins. Arthritis Rheum 2005;52:3433-8.
10. Padyukov L, Seielstad M, Ong RT, Ding B, Ronnelid J, Seddighzadeh M, et al. A genome-wide association study suggests contrasting associations in ACPA-positive versus ACPA-negative rheumatoid arthritis. Ann Rheum Dis 2011;70:259-65.
11. Seddighzadeh M, Gonzalez A, Ding B, Ferreiro-Iglesias A, Gomez-Reino JJ, Rheumatoid Arthritis Network and Coordinated Project, et al. Variants within STAT genes reveal association with anticitrullinated protein antibody-negative rheumatoid arthritis in 2 European populations. J Rheumatol 2012;39:1509-16.
12. Lundstrom E, Kallberg H, Alfredsson L, Klareskog L, Padyukov L. Gene-environment interaction between the DRB1 shared epitope and smoking in the risk of anti-citrullinated protein antibody-positive rheumatoid arthritis: all alleles are important. Arthritis Rheum 2009;6:1597-1603.
13. Farragher TM, Lunt M, Plant D, Bunn DK, Barton A, Symmons DP. Benefit of early treatment in inflammatory polyarthritis patients with anti-cyclic citrullinated peptide antibodies versus those without antibodies. Arthritis Care Res 2010;62:664-75.
14. Forslind K, Ahlmen M, Eberhardt K, Hafstrom I, Svensson B, BARFOT Study Group. Prediction of radiological outcome in early rheumatoid arthritis in clinical practice: role of antibodies to citrullinated peptides (anti-CCP). Ann Rheum Dis 2004;63:1090-5.
15. Kastbom A, Strandberg G, Lindroos A, Skogh T. Anti-CCP antibody test predicts the disease course during 3 years in early rheumatoid arthritis (the Swedish TIRA project). Ann Rheum Dis 2004;63:1085-9.
16. Nell VP, Machold KP, Stamm TA, Eberl G, Heinzl H, Uffmann M, et al. Autoantibody profiling as early diagnostic and prognostic tool for rheumatoid arthritis. Ann Rheum Dis 2005;64:1731-6.
17. da Mota LM, Dos Santos Neto LL, de Carvalho JF, Pereira IA, Burlingame R, Menard HA, et al. The presence of anti-citrullinated protein antibodies (ACPA) and rheumatoid factor on patients with rheumatoid arthritis (RA) does not interfere with the chance of clinical remission in a follow-up of 3 years. Rheumatol Int 2012;32:3807-12.
18. van der Linden MP, van der Woude D, Ioan-Facsinay A, Levarht EW, Stoeken-Rijsbergen G, Huizinga TW, et al. Value of anti-modified citrullinated vimentin and third-generation anti-cyclic citrullinated peptide compared with second-generation anti-cyclic citrullinated peptide and rheumatoid factor in predicting disease outcome in undifferentiated arthritis and rheumatoid arthritis. Arthritis Rheum 2009;60:2232-41.
19. van den Broek M, Dirven L, Klarenbeek NB, Molenaar TH, Han KH, Kerstens PJ, et al. The association of treatment response and joint damage with ACPA-status in recent-onset RA: a subanalysis of the 8-year follow-up of the BeSt study. Ann Rheum Dis 2012;71:245-8.
20. Wagner E, Ammer K, Kolarz G, Krajnc I, Palkonyai E, Scherak O, et al. Predicting factors for severity of rheumatoid arthritis: a prospective multicenter cohort study of 172 patients over 3 years. Rheumatol Int 2007;27:1041-8.
21. Miller A, Mahtani KR, Waterfield MA, Timms A, Misbah SA, Luqmani RA. Is rheumatoid factor useful in primary care? A retrospective cross-sectional study. Clin Rheumatol 2013;32:1089-93.
22. Ursum J, Bos WH, van Dillen N, Dijkmans BA, van Schaardenburg D. Levels of anti-citrullinated protein antibodies and IgM rheumatoid factor are not associated with outcome in early arthritis patients: a cohort study. Arthritis Res Ther 2010;12:R8.
23. Fautrel B, Combe B, Rincheval N, Dougados M, ESPOIR Scientific Committee. Level of agreement of the 1987 ACR and 2010 ACR/EULAR rheumatoid arthritis classification criteria: an analysis based on ESPOIR cohort data. Ann Rheum Dis 2012;71:386-9.
24. Krabben A, Abhishek A, Britsemmer K, Filer A, Huizinga TW, Raza K, et al. Risk of rheumatoid arthritis development in patients with unclassified arthritis according to the 2010 ACR/EULAR criteria for rheumatoid arthritis. Rheumatology 2013;52:1265-70.
25. Barra L, Scinocca M, Saunders S, Bhayana R, Rohekar S, Racape M, et al. Anti-citrullinated protein antibodies in unaffected first-degree relatives of rheumatoid arthritis patients. Arthritis Rheum 2013;65:1439-47.
26. Ioan-Facsinay A, Willemze A, Robinson DB, Peschken CA, Markland J, van der Woude D, et al. Marked differences in fine specificity and isotype usage of the anti-citrullinated protein antibody in health and disease. Arthritis Rheum 2008;58:3000-8.
27. Taylor P, Gartemann J, Hsieh J, Creeden J. A systematic review of serum biomarkers anti-cyclic citrullinated Peptide and rheumatoid factor as tests for rheumatoid arthritis. Autoimmune Dis 2011;2011:815038.
28. Mewar D, Coote A, Moore DJ, Marinou I, Keyworth J, Dickson MC, et al. Independent associations of anti-cyclic citrullinated peptide antibodies and rheumatoid factor with radiographic severity of rheumatoid arthritis. Arthritis Res Ther 2006;8:R128.
29. De Rooy DP, Willemze A, Mertens B, Huizinga TW, Van der Helm-van Mil AH. Can anti-cyclic citrullinated peptide antibody-negative RA be subdivided into clinical subphenotypes? Arthritis Res Ther 2011;13:R180.
30. Shi J, Knevel R, Suwannalai P, van der Linden MP, Janssen GM, van Veelen PA, et al. Autoantibodies recognizing carbamylated proteins are present in sera of patients with rheumatoid arthritis and predict joint damage. Proc Natl Acad Sci U S A 2011;108:17372-7.
31. Scinocca M, Bell DA, Racapé M, Joseph R, Shaw G, McCormick JK, et al. Anti-homocitrullinated fibrinogen antibodies are specific to rheumatoid arthritis and frequently bind citrullinated proteins/peptides. J Rheumatol 2014;41:270-9.